NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the pricing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about June 30, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
